Physician profile
Tad Jackson
NPI 1497722151
$12,772.51
in general payments reported to CMS, 2019-2025
23 companies · $229 in 2025
The $229 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,924 · 2020: $683 · 2021: $853 · 2022: $1,360 · 2023: $1,376 · 2024: $1,348 · 2025: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,688 · Education: $264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,687.85 |
| Education | $264.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $5,177.58 | 2019-2022 | |
| Glaxosmithkline, LLC. | $2,012.14 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $1,549.73 | 2019-2025 | Tezspire, Breztri, Fasenra |
| Regeneron Healthcare Solutions, INC. | $882.25 | 2019-2024 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $705.49 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Genzyme Corporation | $576.74 | 2019-2024 | |
| Genentech USA, INC. | $529.51 | 2019-2024 | Xolair |
| Novartis Pharmaceuticals Corporation | $235.46 | 2019 | |
| Philips North America LLC | $199.91 | 2019-2021 | |
| United Therapeutics Corporation | $162.35 | 2019-2022 | |
| Harmony Biosciences LLC | $146.43 | 2021-2024 | Wakix |
| Jazz Pharmaceuticals INC. | $128.74 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $98.99 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $90.24 | 2020-2022 | |
| Inspire Medical Systems, INC. | $47.79 | 2023 | Inspire |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $43.47 | 2023-2024 | Quviviq |
| Allergan, INC. | $41.23 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $40.89 | 2019-2020 | |
| Abbvie INC. | $28.17 | 2021 | |
| Vifor Pharma, INC. | $21.78 | 2024 | Zemaira |
| Merck Sharp & Dohme LLC | $21.28 | 2022 | |
| Novo Nordisk INC | $17.55 | 2019 | |
| Resmed Corp | $14.79 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tad Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.